SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Visiongain | PRODUCT CODE: 2151275

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2151275

Global Peptide Contract Manufacturing Market Report 2026-2036

PUBLISHED:
PAGES: 376 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5872.50
PDF (Team License - Up to 6 Users)
USD 6952.50
PDF (Site License)
USD 8167.50
PDF (Enterprise License - Includes Free Datasets)
USD 10320.75

Add to Cart

Description

Table of Contents

List of Tables

This report provides a comprehensive analysis of the market including market size, growth drivers, competitive positioning, and revenue forecasts across synthesis type, scale of operation, service type, therapeutic area, and end-user segments.

Greater Use of Automation and Advanced Process Control

Peptide manufacturers are increasing their use of automation, digital monitoring and advanced process controls to improve consistency, productivity and traceability. Automated synthesis platforms can control reagent addition, coupling, deprotection and washing cycles, while integrated data systems allow manufacturers to monitor process performance and identify deviations. These capabilities are particularly valuable in commercial-scale peptide production, where small variations across repeated synthesis cycles can affect yield and impurity profiles.

Almac has developed a digital approach to peptide process development that addresses limitations and potential errors associated with conventional solid-phase peptide synthesis. The company also uses automated synthesis protocols capable of completing several amino-acid couplings per day, supporting more consistent and efficient peptide production. Wider adoption of digitalised processing can reduce manual intervention, accelerate deviation investigations and improve batch-to-batch reproducibility. This trend will strengthen the competitive position of CDMOs combining experienced process-development teams with modern manufacturing, automation and analytical infrastructure.

Report Scope and Data Coverage

  • Global peptide contract manufacturing market analysis
  • Revenue forecasts to 2036 with annual growth estimates
  • Segment-level modelling across synthesis type, scale of operation, service type, therapeutic area, and end-user
  • Regional and national market forecasts across five regions and 14 leading national markets
  • Competitive intelligence on 17 leading companies

Includes both quantitative forecasting and qualitative strategic analysis covering technology, competition, trade dynamics, and supply chain developments.

Our 350-page report provides 125 tables and 175 charts/graphs.

Segmentation Framework

By Type of Synthesis

  • Chemical Synthesis
  • Non-chemical Synthesis

By Scale of Operation

  • Preclinical / Clinical
  • Commercial

By Service Type

  • Process Development and Scale-up
  • Peptide API Manufacturing
  • Formulation and Drug Product Manufacturing
  • Fill-Finish and Packaging
  • Analytical Testing and Quality Control

By Therapeutic Area

  • Oncology
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Central Nervous System Disorders
  • Other Therapeutic Areas

By End-User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Generic Drug Manufacturers
  • Academic and Research Institutions

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East and Africa

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 17 leading companies, including:

  • Ajinomoto Bio-Pharma Services
  • Almac Group
  • AmbioPharm, Inc.
  • Bachem Holding AG
  • Cambrex Corporation
  • CordenPharma
  • BCN Peptides
  • CPC Scientific Inc.
  • CSBio
  • Hybio Pharmaceutical Co., Ltd.
  • Lonza Group AG
  • Olon S.p.A.
  • Peptide Institute, Inc.
  • Piramal Pharma Solutions
  • PolyPeptide Group AG
  • ScinoPharm Taiwan, Ltd.
  • WuXi TIDES

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Technology capabilities and programme wins
  • Strategic outlook

Key Questions Answered

  • How is the peptide contract manufacturing market evolving?
  • What is driving and restraining the peptide contract manufacturing market?
  • How will each peptide contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each peptide contract manufacturing submarket develop from 2026 to 2036?
  • Will leading peptide contract manufacturing markets broadly follow macroeconomic dynamics, or will individual national markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2026 and 2036?
  • What are the best investment options for new product and service lines?

Bespoke Intelligence and Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements. This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Supply chain and sourcing intelligence
  • Peptide synthesis technology and capacity assessment
  • Scenario modelling including tariff and geopolitical risk

Why This Market Intelligence Matters

The peptide contract manufacturing market is entering a period of accelerated structural growth driven by surging GLP-1 and metabolic peptide demand, pipeline expansion into oncology and CNS disorders, and increasing reliance on specialist CDMOs for complex synthesis, purification, formulation and fill-finish services. CDMOs that combine large-scale solid-phase synthesis capability, integrated API-to-drug-product services, and advanced automation are best positioned to secure long-term commercial contracts across the next decade.

Show more
Product Code: PHA1400

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Peptide Contract Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Impact Analysis
  • 3.3 Market Driving Factors
  • 3.4 Market Restraining Factors
  • 3.5 Market Opportunities
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Suppliers
    • 3.6.2 Bargaining Power of Buyers
    • 3.6.3 Competitive Rivalry
    • 3.6.4 Threat of Substitutes
    • 3.6.5 Threat of New Entrants
  • 3.7 PEST Analysis
  • 3.8 U.S. Tariffs: What's the Impact on Global Peptide Contract Manufacturing Market?
    • 3.8.1 Overview
    • 3.8.2 V-Shaped Recovery Scenario
      • 3.8.2.1 Why V-Shaped Recovery?
      • 3.8.2.2 Impact from Tariffs
      • 3.8.2.3 Market Dynamics and Demand Recovery
      • 3.8.2.4 Policy and Funding Support
      • 3.8.2.5 Timeframe for Recovery
  • 3.9 U-Shaped Recovery Scenario
      • 3.9.1.1 Why U-Shaped Recovery?
      • 3.9.1.2 Impact from Tariffs
      • 3.9.1.3 Market Dynamics and Demand Recovery
      • 3.9.1.4 Policy and Funding Support
      • 3.9.1.5 Timeframe for Recovery
  • 3.10 L-Shaped Recovery Scenario
      • 3.10.1.1 Why L-Shaped Recovery?
      • 3.10.1.2 Impact from Tariffs
      • 3.10.1.3 Market Dynamics and Demand Recovery
      • 3.10.1.4 Policy and Funding Support
      • 3.10.1.5 Timeframe for Recovery
  • 3.11 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
  • 3.12 Impact of U.S. and China Trade War on Peptide Contract Manufacturing Market
  • 3.13 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?

4 Peptide Contract Manufacturing Market Analysis by Type of Synthesis (US$ Million, AGR %)

  • 4.1 Key Findings
  • 4.2 Type of Synthesis Segment: Market Attractiveness Index
  • 4.3 Chemical Synthesis
    • 4.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.3.2 Market Share by Region, 2026 & 2036 (%)
  • 4.4 Non-chemical Synthesis
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)

5 Peptide Contract Manufacturing Market Analysis by Scale of Operation (US$ Million, AGR %)

  • 5.1 Key Findings
  • 5.2 Scale of Operation Segment: Market Attractiveness Index
  • 5.3 Preclinical / Clinical
    • 5.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.3.2 Market Share by Region, 2026 & 2036 (%)
  • 5.4 Commercial
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)

6 Peptide Contract Manufacturing Market Analysis by Service Type (US$ Million, AGR %)

  • 6.1 Key Findings
  • 6.2 Service Type Segment: Market Attractiveness Index
  • 6.3 Process Development and Scale-up
    • 6.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.3.2 Market Share by Region, 2026 & 2036 (%)
  • 6.4 Peptide API Manufacturing
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Formulation and Drug Product Manufacturing
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)
  • 6.6 Fill-Finish and Packaging
    • 6.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.6.2 Market Share by Region, 2026 & 2036 (%)
  • 6.7 Analytical Testing and Quality Control
    • 6.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.7.2 Market Share by Region, 2026 & 2036 (%)

7 Peptide Contract Manufacturing Market Analysis by Therapeutic Area (US$ Million, AGR %)

  • 7.1 Key Findings
  • 7.2 Therapeutic Area Segment: Market Attractiveness Index
  • 7.3 Oncology
    • 7.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.3.2 Market Share by Region, 2026 & 2036 (%)
  • 7.4 Metabolic Diseases
    • 7.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Cardiovascular Diseases
    • 7.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Infectious Diseases
    • 7.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 Central Nervous System Disorders
    • 7.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.7.2 Market Share by Region, 2026 & 2036 (%)
  • 7.8 Other Therapeutic Areas
    • 7.8.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.8.2 Market Share by Region, 2026 & 2036 (%)

8 Peptide Contract Manufacturing Market Analysis by End-users (US$ Million, AGR %)

  • 8.1 Key Findings
  • 8.2 End-users Segment: Market Attractiveness Index
  • 8.3 Pharmaceutical Companies
    • 8.3.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.3.2 Market Share by Region, 2026 & 2036 (%)
  • 8.4 Biotechnology Companies
    • 8.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Generic Drug Manufacturers
    • 8.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Academic and Research Institutions
    • 8.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)

9 Peptide Contract Manufacturing Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Peptide Contract Manufacturing Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Peptide Contract Manufacturing Market Attractiveness Index
  • 10.3 North America Peptide Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 North America Peptide Contract Manufacturing Market Size Estimation and Forecast by Country
  • 10.5 North America Peptide Contract Manufacturing Market Size Estimation and Forecast by Type of Synthesis
  • 10.6 North America Peptide Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 10.7 North America Peptide Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 10.8 North America Peptide Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
  • 10.9 North America Peptide Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 10.10 U.S. Peptide Contract Manufacturing Market Analysis
  • 10.11 Canada Peptide Contract Manufacturing Market Analysis

11 Europe Peptide Contract Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Peptide Contract Manufacturing Market Attractiveness Index
  • 11.3 Europe Peptide Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Europe Peptide Contract Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 Europe Peptide Contract Manufacturing Market Size Estimation and Forecast by Type of Synthesis
  • 11.6 Europe Peptide Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 11.7 Europe Peptide Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 11.8 Europe Peptide Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
  • 11.9 Europe Peptide Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 11.10 Germany Peptide Contract Manufacturing Market Analysis
  • 11.11 UK Peptide Contract Manufacturing Market Analysis
  • 11.12 France Peptide Contract Manufacturing Market Analysis
  • 11.13 Italy Peptide Contract Manufacturing Market Analysis
  • 11.14 Rest of Europe Peptide Contract Manufacturing Market Analysis

12 Asia Pacific Peptide Contract Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Peptide Contract Manufacturing Market Attractiveness Index
  • 12.3 Asia Pacific Peptide Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Asia Pacific Peptide Contract Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Peptide Contract Manufacturing Market Size Estimation and Forecast by Type of Synthesis
  • 12.6 Asia Pacific Peptide Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 12.7 Asia Pacific Peptide Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 12.8 Asia Pacific Peptide Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
  • 12.9 Asia Pacific Peptide Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 12.10 Japan Peptide Contract Manufacturing Market Analysis
  • 12.11 China Peptide Contract Manufacturing Market Analysis
  • 12.12 India Peptide Contract Manufacturing Market Analysis
  • 12.13 Australia Peptide Contract Manufacturing Market Analysis
  • 12.14 Rest of Asia Pacific Peptide Contract Manufacturing Market Analysis

13 Latin America Peptide Contract Manufacturing Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Peptide Contract Manufacturing Market Attractiveness Index
  • 13.3 Latin America Peptide Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 13.4 Latin America Peptide Contract Manufacturing Market Size Estimation and Forecast by Country
  • 13.5 Latin America Peptide Contract Manufacturing Market Size Estimation and Forecast by Type of Synthesis
  • 13.6 Latin America Peptide Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 13.7 Latin America Peptide Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 13.8 Latin America Peptide Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
  • 13.9 Latin America Peptide Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 13.10 Brazil Peptide Contract Manufacturing Market Analysis
  • 13.11 Mexico Peptide Contract Manufacturing Market Analysis
  • 13.12 Rest of Latin America Peptide Contract Manufacturing Market Analysis

14 MEA Peptide Contract Manufacturing Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Peptide Contract Manufacturing Market Attractiveness Index
  • 14.3 MEA Peptide Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 14.4 MEA Peptide Contract Manufacturing Market Size Estimation and Forecast by Country
  • 14.5 MEA Peptide Contract Manufacturing Market Size Estimation and Forecast by Type of Synthesis
  • 14.6 MEA Peptide Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 14.7 MEA Peptide Contract Manufacturing Market Size Estimation and Forecast by Service Type
  • 14.8 MEA Peptide Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
  • 14.9 MEA Peptide Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 14.10 GCC Peptide Contract Manufacturing Market Analysis
  • 14.11 South Africa Peptide Contract Manufacturing Market Analysis
  • 14.12 Rest of MEA Peptide Contract Manufacturing Market Analysis

15 Company Profiles

  • 15.1 Ajinomoto Bio-Pharma Services
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Company Financials
      • 15.1.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.1.3.2 R&D, 2022-2025 (US$ Million)
      • 15.1.3.3 Business Segment Market Shares (%), 2025
      • 15.1.3.4 Geographic Segment Market Shares (%), 2025
    • 15.1.4 Service Benchmarking
    • 15.1.5 Strategic Outlook
  • 15.2 Almac Group
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Company Financials
      • 15.2.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.2.3.2 R&D, 2022-2025 (US$ Million)
      • 15.2.3.3 Business Segment Market Shares (%), 2025
      • 15.2.3.4 Geographic Segment Market Shares (%), 2025
    • 15.2.4 Service Benchmarking
    • 15.2.5 Strategic Outlook
  • 15.3 AmbioPharm, Inc.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Company Financials
      • 15.3.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.3.3.2 R&D, 2022-2025 (US$ Million)
      • 15.3.3.3 Business Segment Market Shares (%), 2025
      • 15.3.3.4 Geographic Segment Market Shares (%), 2025
    • 15.3.4 Service Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 Bachem Holding AG
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Company Financials
      • 15.4.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.4.3.2 R&D, 2022-2025 (US$ Million)
      • 15.4.3.3 Business Segment Market Shares (%), 2025
      • 15.4.3.4 Geographic Segment Market Shares (%), 2025
    • 15.4.4 Service Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Cambrex Corporation
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Company Financials
      • 15.5.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.5.3.2 R&D, 2022-2025 (US$ Million)
      • 15.5.3.3 Business Segment Market Shares (%), 2025
      • 15.5.3.4 Geographic Segment Market Shares (%), 2025
    • 15.5.4 Service Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 CordenPharma
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Company Financials
      • 15.6.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.6.3.2 R&D, 2022-2025 (US$ Million)
      • 15.6.3.3 Business Segment Market Shares (%), 2025
      • 15.6.3.4 Geographic Segment Market Shares (%), 2025
    • 15.6.4 Service Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 BCN Peptides
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Company Financials
      • 15.7.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.7.3.2 R&D, 2022-2025 (US$ Million)
      • 15.7.3.3 Business Segment Market Shares (%), 2025
      • 15.7.3.4 Geographic Segment Market Shares (%), 2025
    • 15.7.4 Service Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 CPC Scientific Inc.
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Company Financials
      • 15.8.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.8.3.2 R&D, 2022-2025 (US$ Million)
      • 15.8.3.3 Business Segment Market Shares (%), 2025
      • 15.8.3.4 Geographic Segment Market Shares (%), 2025
    • 15.8.4 Service Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 CSBio
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Company Financials
      • 15.9.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.9.3.2 R&D, 2022-2025 (US$ Million)
      • 15.9.3.3 Business Segment Market Shares (%), 2025
      • 15.9.3.4 Geographic Segment Market Shares (%), 2025
    • 15.9.4 Service Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 Hybio Pharmaceutical Co., Ltd.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Company Financials
      • 15.10.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.10.3.2 R&D, 2022-2025 (US$ Million)
      • 15.10.3.3 Business Segment Market Shares (%), 2025
      • 15.10.3.4 Geographic Segment Market Shares (%), 2025
    • 15.10.4 Service Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 Lonza Group AG
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Company Financials
      • 15.11.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.11.3.2 R&D, 2022-2025 (US$ Million)
      • 15.11.3.3 Business Segment Market Shares (%), 2025
      • 15.11.3.4 Geographic Segment Market Shares (%), 2025
    • 15.11.4 Service Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 Olon S.p.A.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Company Financials
      • 15.12.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.12.3.2 R&D, 2022-2025 (US$ Million)
      • 15.12.3.3 Business Segment Market Shares (%), 2025
      • 15.12.3.4 Geographic Segment Market Shares (%), 2025
    • 15.12.4 Service Benchmarking
    • 15.12.5 Strategic Outlook
  • 15.13 Peptide Institute, Inc.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Company Financials
      • 15.13.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.13.3.2 R&D, 2022-2025 (US$ Million)
      • 15.13.3.3 Business Segment Market Shares (%), 2025
      • 15.13.3.4 Geographic Segment Market Shares (%), 2025
    • 15.13.4 Service Benchmarking
    • 15.13.5 Strategic Outlook
  • 15.14 Piramal Pharma Solutions
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Company Financials
      • 15.14.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.14.3.2 R&D, 2022-2025 (US$ Million)
      • 15.14.3.3 Business Segment Market Shares (%), 2025
      • 15.14.3.4 Geographic Segment Market Shares (%), 2025
    • 15.14.4 Service Benchmarking
    • 15.14.5 Strategic Outlook
  • 15.15 PolyPeptide Group AG
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Company Financials
      • 15.15.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.15.3.2 R&D, 2022-2025 (US$ Million)
      • 15.15.3.3 Business Segment Market Shares (%), 2025
      • 15.15.3.4 Geographic Segment Market Shares (%), 2025
    • 15.15.4 Service Benchmarking
    • 15.15.5 Strategic Outlook
  • 15.16 ScinoPharm Taiwan, Ltd.
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Company Financials
      • 15.16.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.16.3.2 R&D, 2022-2025 (US$ Million)
      • 15.16.3.3 Business Segment Market Shares (%), 2025
      • 15.16.3.4 Geographic Segment Market Shares (%), 2025
    • 15.16.4 Service Benchmarking
    • 15.16.5 Strategic Outlook
  • 15.17 WuXi TIDES
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Company Financials
      • 15.17.3.1 Revenue, 2022-2025 (US$ Million)
      • 15.17.3.2 R&D, 2022-2025 (US$ Million)
      • 15.17.3.3 Business Segment Market Shares (%), 2025
      • 15.17.3.4 Geographic Segment Market Shares (%), 2025
    • 15.17.4 Service Benchmarking
    • 15.17.5 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
Show more
Product Code: PHA1400

List of Tables

  • Table 1 Peptide Contract Manufacturing Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
  • Table 2 Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 3 Chemical Synthesis Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 4 Non-chemical Synthesis Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 5 Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 6 Preclinical / Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 7 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 8 Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 9 Process Development and Scale-up Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 10 Peptide API Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 11 Formulation and Drug Product Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 12 Fill-Finish and Packaging Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 13 Analytical Testing and Quality Control Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 14 Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 15 Oncology Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 16 Metabolic Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 17 Cardiovascular Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 18 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 19 Central Nervous System Disorders Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 20 Other Therapeutic Areas Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 21 Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 22 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 23 Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 24 Generic Drug Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 25 Academic and Research Institutions Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 26 Peptide Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 27 North America Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 28 North America Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 29 North America Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 30 North America Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 31 North America Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 32 North America Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 33 U.S. Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 34 Canada Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 35 Europe Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 36 Europe Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 37 Europe Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 38 Europe Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 39 Europe Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 40 Europe Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 41 Germany Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 42 UK Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 43 France Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 44 Italy Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 45 Rest of Europe Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 46 Asia Pacific Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 47 Asia Pacific Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 48 Asia Pacific Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 49 Asia Pacific Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 50 Asia Pacific Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 51 Asia Pacific Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 52 Japan Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 53 China Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 54 India Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 55 Australia Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 56 Rest of Asia Pacific Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 57 Latin America Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 58 Latin America Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 59 Latin America Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 60 Latin America Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 61 Latin America Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 62 Latin America Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 63 Brazil Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 64 Mexico Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 65 Rest of Latin America Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 66 MEA Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 67 MEA Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 68 MEA Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 69 MEA Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 70 MEA Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 71 MEA Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 72 GCC Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 73 South Africa Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 74 Rest of MEA Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 75 Ajinomoto Bio-Pharma Services: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Ajinomoto Bio-Pharma Services: Service Benchmarking
  • Table 77 Ajinomoto Bio-Pharma Services: Strategic Outlook
  • Table 78 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Almac Group: Service Benchmarking
  • Table 80 Almac Group: Strategic Outlook
  • Table 81 AmbioPharm, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 AmbioPharm, Inc.: Service Benchmarking
  • Table 83 AmbioPharm, Inc.: Strategic Outlook
  • Table 84 Bachem Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Bachem Holding AG: Service Benchmarking
  • Table 86 Bachem Holding AG: Strategic Outlook
  • Table 87 Cambrex Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Cambrex Corporation: Service Benchmarking
  • Table 89 Cambrex Corporation: Strategic Outlook
  • Table 90 CordenPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 CordenPharma: Service Benchmarking
  • Table 92 CordenPharma: Strategic Outlook
  • Table 93 BCN Peptides: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 BCN Peptides: Service Benchmarking
  • Table 95 BCN Peptides: Strategic Outlook
  • Table 96 CPC Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 CPC Scientific Inc.: Service Benchmarking
  • Table 98 CPC Scientific Inc.: Strategic Outlook
  • Table 99 CSBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 CSBio: Service Benchmarking
  • Table 101 CSBio: Strategic Outlook
  • Table 102 Hybio Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Hybio Pharmaceutical Co., Ltd.: Service Benchmarking
  • Table 104 Hybio Pharmaceutical Co., Ltd.: Strategic Outlook
  • Table 105 Lonza Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Lonza Group AG: Service Benchmarking
  • Table 107 Lonza Group AG: Strategic Outlook
  • Table 108 Olon S.p.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 Olon S.p.A.: Service Benchmarking
  • Table 110 Olon S.p.A.: Strategic Outlook
  • Table 111 Peptide Institute, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Peptide Institute, Inc.: Service Benchmarking
  • Table 113 Peptide Institute, Inc.: Strategic Outlook
  • Table 114 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Piramal Pharma Solutions: Service Benchmarking
  • Table 116 Piramal Pharma Solutions: Strategic Outlook
  • Table 117 PolyPeptide Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 PolyPeptide Group AG: Service Benchmarking
  • Table 119 PolyPeptide Group AG: Strategic Outlook
  • Table 120 ScinoPharm Taiwan, Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 ScinoPharm Taiwan, Ltd.: Service Benchmarking
  • Table 122 ScinoPharm Taiwan, Ltd.: Strategic Outlook
  • Table 123 WuXi TIDES: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 WuXi TIDES: Service Benchmarking
  • Table 125 WuXi TIDES: Strategic Outlook

List of Figures

  • Figure 1 Peptide Contract Manufacturing Market Segmentation
  • Figure 2 Peptide Contract Manufacturing Market by Type of Synthesis: Market Attractiveness Index
  • Figure 3 Peptide Contract Manufacturing Market by Scale of Operation: Market Attractiveness Index
  • Figure 4 Peptide Contract Manufacturing Market by Service Type: Market Attractiveness Index
  • Figure 5 Peptide Contract Manufacturing Market by Therapeutic Area: Market Attractiveness Index
  • Figure 6 Peptide Contract Manufacturing Market by End-users: Market Attractiveness Index
  • Figure 7 Peptide Contract Manufacturing Market Attractiveness Index by Region
  • Figure 8 Peptide Contract Manufacturing Market: Market Dynamics
  • Figure 9 Peptide Contract Manufacturing Market: Porter's Five Forces Analysis
  • Figure 10 Peptide Contract Manufacturing Market: PEST Analysis
  • Figure 11 Peptide Contract Manufacturing Market Attractiveness Index by Type of Synthesis
  • Figure 12 Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %)
  • Figure 13 Peptide Contract Manufacturing Market Share Forecast by Type of Synthesis, 2026, 2031, 2036 (%)
  • Figure 14 Chemical Synthesis Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 15 Chemical Synthesis Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 16 Non-chemical Synthesis Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 17 Non-chemical Synthesis Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 18 Peptide Contract Manufacturing Market Attractiveness Index by Scale of Operation
  • Figure 19 Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 20 Peptide Contract Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 21 Preclinical / Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 22 Preclinical / Clinical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 23 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 24 Commercial Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 25 Peptide Contract Manufacturing Market Attractiveness Index by Service Type
  • Figure 26 Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 27 Peptide Contract Manufacturing Market Share Forecast by Service Type, 2026, 2031, 2036 (%)
  • Figure 28 Process Development and Scale-up Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 29 Process Development and Scale-up Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 Peptide API Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 31 Peptide API Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 32 Formulation and Drug Product Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 33 Formulation and Drug Product Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 34 Fill-Finish and Packaging Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 35 Fill-Finish and Packaging Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 36 Analytical Testing and Quality Control Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 37 Analytical Testing and Quality Control Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 38 Peptide Contract Manufacturing Market Attractiveness Index by Therapeutic Area
  • Figure 39 Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %)
  • Figure 40 Peptide Contract Manufacturing Market Share Forecast by Therapeutic Area, 2026, 2031, 2036 (%)
  • Figure 41 Oncology Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 42 Oncology Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 43 Metabolic Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 44 Metabolic Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 45 Cardiovascular Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 46 Cardiovascular Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 47 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 48 Infectious Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 49 Central Nervous System Disorders Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 50 Central Nervous System Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 51 Other Therapeutic Areas Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 52 Other Therapeutic Areas Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 53 Peptide Contract Manufacturing Market Attractiveness Index by End-users
  • Figure 54 Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 55 Peptide Contract Manufacturing Market Share Forecast by End-users, 2026, 2031, 2036 (%)
  • Figure 56 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 57 Pharmaceutical Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 58 Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 59 Biotechnology Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 60 Generic Drug Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 61 Generic Drug Manufacturers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 62 Academic and Research Institutions Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 63 Academic and Research Institutions Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 64 Peptide Contract Manufacturing Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 65 Peptide Contract Manufacturing Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 66 Peptide Contract Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 67 North America Peptide Contract Manufacturing Market Attractiveness Index
  • Figure 68 North America Peptide Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 69 North America Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 70 North America Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %)
  • Figure 71 North America Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 72 North America Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 73 North America Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %)
  • Figure 74 North America Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 75 U.S. Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 76 Canada Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 77 Europe Peptide Contract Manufacturing Market Attractiveness Index
  • Figure 78 Europe Peptide Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 79 Europe Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 80 Europe Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %)
  • Figure 81 Europe Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 82 Europe Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 83 Europe Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %)
  • Figure 84 Europe Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 85 Germany Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 86 UK Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 87 France Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 88 Italy Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 89 Rest of Europe Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 90 Asia Pacific Peptide Contract Manufacturing Market Attractiveness Index
  • Figure 91 Asia Pacific Peptide Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 92 Asia Pacific Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 93 Asia Pacific Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %)
  • Figure 94 Asia Pacific Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 95 Asia Pacific Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 96 Asia Pacific Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %)
  • Figure 97 Asia Pacific Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 98 Japan Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 99 China Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 100 India Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 101 Australia Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 102 Rest of Asia Pacific Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 103 Latin America Peptide Contract Manufacturing Market Attractiveness Index
  • Figure 104 Latin America Peptide Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 105 Latin America Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 106 Latin America Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %)
  • Figure 107 Latin America Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 108 Latin America Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 109 Latin America Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %)
  • Figure 110 Latin America Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 111 Brazil Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 112 Mexico Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 113 Rest of Latin America Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 114 MEA Peptide Contract Manufacturing Market Attractiveness Index
  • Figure 115 MEA Peptide Contract Manufacturing Market by Region, 2026, 2031, 2036 (US$ Million)
  • Figure 116 MEA Peptide Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 117 MEA Peptide Contract Manufacturing Market Forecast by Type of Synthesis, 2026-2036 (US$ Million, AGR %)
  • Figure 118 MEA Peptide Contract Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 119 MEA Peptide Contract Manufacturing Market Forecast by Service Type, 2026-2036 (US$ Million, AGR %)
  • Figure 120 MEA Peptide Contract Manufacturing Market Forecast by Therapeutic Area, 2026-2036 (US$ Million, AGR %)
  • Figure 121 MEA Peptide Contract Manufacturing Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 122 GCC Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 123 South Africa Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 124 Rest of MEA Peptide Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 125 Ajinomoto Bio-Pharma Services: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 126 Ajinomoto Bio-Pharma Services: Regional Market Shares (%), 2025
  • Figure 127 Ajinomoto Bio-Pharma Services: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 128 Almac Group: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 129 Almac Group: Regional Market Shares (%), 2025
  • Figure 130 Almac Group: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 131 AmbioPharm, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 132 AmbioPharm, Inc.: Regional Market Shares (%), 2025
  • Figure 133 AmbioPharm, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 134 Bachem Holding AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 135 Bachem Holding AG: Regional Market Shares (%), 2025
  • Figure 136 Bachem Holding AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 137 Cambrex Corporatoon: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 138 Cambrex Corporatoon: Regional Market Shares (%), 2025
  • Figure 139 Cambrex Corporatoon: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 140 CordenPharma: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 141 CordenPharma: Regional Market Shares (%), 2025
  • Figure 142 CordenPharma: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 143 BCN Peptides: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 144 BCN Peptides: Regional Market Shares (%), 2025
  • Figure 145 BCN Peptides: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 146 CPC Scientific Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 147 CPC Scientific Inc.: Regional Market Shares (%), 2025
  • Figure 148 CPC Scientific Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 149 CSBio: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 150 CSBio: Regional Market Shares (%), 2025
  • Figure 151 CSBio: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 152 Hybio Pharmaceutical Co., Ltd.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 153 Hybio Pharmaceutical Co., Ltd.: Regional Market Shares (%), 2025
  • Figure 154 Hybio Pharmaceutical Co., Ltd.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 155 Lonza Group AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 156 Lonza Group AG: Regional Market Shares (%), 2025
  • Figure 157 Lonza Group AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 158 Olon S.p.A.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 159 Olon S.p.A.: Regional Market Shares (%), 2025
  • Figure 160 Olon S.p.A.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 161 Peptide Institute, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 162 Peptide Institute, Inc.: Regional Market Shares (%), 2025
  • Figure 163 Peptide Institute, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 164 Piramal Pharma Solutions: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 165 Piramal Pharma Solutions: Regional Market Shares (%), 2025
  • Figure 166 Piramal Pharma Solutions: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 167 PolyPeptide Group AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 168 PolyPeptide Group AG: Regional Market Shares (%), 2025
  • Figure 169 PolyPeptide Group AG: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 170 ScinoPharm Taiwan, Ltd.: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 171 ScinoPharm Taiwan, Ltd.: Regional Market Shares (%), 2025
  • Figure 172 ScinoPharm Taiwan, Ltd.: R&D, 2022-2025 (US$ Million, AGR %)
  • Figure 173 WuXi TIDES: Net Revenue, 2022-2025 (US$ Million, AGR %)
  • Figure 174 WuXi TIDES: Regional Market Shares (%), 2025
  • Figure 175 WuXi TIDES: R&D, 2022-2025 (US$ Million, AGR %)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!